Silence Therapeutics names Simon Sturge as Chairman, and appoints Alastair Riddell and Stephen Parker as independent Non-Executive Directors

– UK, London – Silence Therapeutics plc (AIM: SLN) announces today that Jerry Randall will be stepping down as Executive Chairman of Silence, with immediate effect. He will be succeeded by Simon Sturge, a current non-executive director of the Company as Chairman, in a non-executive capacity.

The Company also announces the appointment of Dr Alastair Riddell and Dr Stephen Parker as independent non-executive directors.

Dr Alastair Riddell, age 64, has over 30 years of experience in the Pharmaceutical and Biotech industries. Between 2000 and 2010 he was a main board member of the Bioindustry Association of Great Britain. He was chief executive of Stem Cell Sciences plc, 2007 to 2009, Pharmagene plc, 1998 to 2005, and of Paradigm Therapeutics Limited, 2005 to 2007.

Dr Stephen Parker, age 55, is executive chairman of Cantab Biopharmaceuticals and a partner in Celtic Pharma Holdings Advisors. His career in the healthcare and pharma sector spans over 30 years, including six in City in advisory roles and two years as finance director of Oxford Glycosciences plc.

The Board Committees will be chaired as follows:

  • – Remuneration: Alastair Riddell
  • – Nominations: Simon Sturge
  • – Audit: Stephen Parker

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Comments are closed.